This study is being done to evaluate the efficacy and safety of asenapine as compared to placebo in preventing the recurrence of mood episodes after stabilization of an acute/manic mixed episode in participants with Bipolar 1 Disorder. After a Screening Period, each participant will receive open-label asenapine and matching placebo for 12 to 16 weeks. Participants who meet stabilization criteria may then be randomized into one of the two study arms (asenapine or matching placebo) to receive double-blind treatment for up to an additional 26-weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
561
asenapine, sublingual tablets, 5 to 10 mg twice per day (BID)
asenapine-matched placebo, sublingual tablets, BID
Forest Investigative Site 3017
Anaheim, California, United States
Forest Investigative Site 3019
Chino, California, United States
Forest Investigative Site 3001
Escondido, California, United States
Forest Investigative Site 3004
National City, California, United States
Forest Investigative Site 3006
Oakland, California, United States
The time (in days) to recurrence of any mood event during the double-blind treatment period
Time frame: From Week 12 or 16 to Week 38 or 42
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Forest Investigative Site 3003
Orange, California, United States
Forest Investigative Site 3007
Torrance, California, United States
Forest Investigative Site 3042
Colorado Springs, Colorado, United States
Forest Investigative Site 3012
Jacksonville, Florida, United States
Forest Investigative Site 3040
Kissimmee, Florida, United States
...and 70 more locations